Marker Therapeutics Financial Performance in Q3
Tuesday, 26 March 2024, 05:13
Marker Therapeutics Q3 Financial Performance
Marker Therapeutics reported a GAAP EPS of -$1.59 and revenue of $3.31 million in the latest quarterly results.
Key Points:
- GAAP EPS: -$1.59
- Revenue: $3.31 million
Despite the decline in earnings, Marker Therapeutics' revenue remained steady, indicating a resilient business model.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.